Literature DB >> 19008464

Mutations within the TNF-like core domain of RANKL impair osteoclast differentiation and activation.

Taksum Cheng1, Nathan J Pavlos, Cathy Wang, Jamie We-Yin Tan, Jian Ming Lin, Jillian Cornish, Ming-Hao Zheng, Jiake Xu.   

Abstract

Receptor activator of nuclear factor-kappaB ligand (RANKL) is a key factor necessary for osteoclast differentiation and activation. Mutations within the TNF-like core domain of RANKL have been recently reported in patients with osteoclast-poor autosomal recessive osteopetrosis. However, the functional consequence owing to RANKL mutations has not been well characterized. Here we describe the functional propensity of RANKL mutants in osteoclast differentiation and their impact on RANKL-mediated signaling cascades. Recombinant RANKL (rRANKL) mutants within the TNF-like core domain exhibited diminished osteoclastogenic potential as compared with wild-type rRANKL1 encoding the full TNF-like core domain [amino acids (aa) 160-318]. Consistent with the insufficient activities on osteoclastogenesis, rRANKL mutants showed reduced activation of nuclear factor-kappaB, IkappaBalpha degradation, and ERK phosphorylation. In addition, we found that rRANKL mutants interfered with wild-type rRANKL-induced osteoclastogenesis with deletion mutant rRANKL5 (aa 246-318) exhibiting the greatest inhibitory effect. The same mutant also significantly reduced wild-type rRANKL1 (aa 160-318)-induced osteoclastic bone resorption in vitro. BIAcore assays demonstrated that rRANKL5 alone, lacking the AA'' and CD loops, weakly binds to receptor activator of nuclear factor-kappaB (RANK). Intriguingly, preincubation of mutant rRANKL5 with rRANKL1 before exposure to RANK enhanced the maximal binding level to RANK, indicating that rRANKL5 forms hybrid trimeric complexes with rRANKL1. Furthermore, RANKL mutant mimicking human RANKL V277 mutation in patients, impairs osteoclast differentiation and signaling. Taken together, these data lend support to the notion that the TNF-like core domain of RANKL contains structural determinants that are crucial for osteoclast differentiation and activation, thus providing a possible mechanistic explanation for the observed phenotype in osteopetrotic patients harboring RANKL mutations.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19008464      PMCID: PMC5419323          DOI: 10.1210/me.2007-0465

Source DB:  PubMed          Journal:  Mol Endocrinol        ISSN: 0888-8809


  35 in total

Review 1.  Mimotopes of viral antigens and biologically important molecules as candidate vaccines and potential immunotherapeutics.

Authors:  C D Partidos; M W Steward
Journal:  Comb Chem High Throughput Screen       Date:  2002-02       Impact factor: 1.339

2.  Cloning, sequencing, and functional characterization of the rat homologue of receptor activator of NF-kappaB ligand.

Authors:  J Xu; J W Tan; L Huang; X H Gao; R Laird; D Liu; S Wysocki; M H Zheng
Journal:  J Bone Miner Res       Date:  2000-11       Impact factor: 6.741

3.  Gene expression of osteoprotegerin ligand, osteoprotegerin, and receptor activator of NF-kappaB in giant cell tumor of bone: possible involvement in tumor cell-induced osteoclast-like cell formation.

Authors:  L Huang; J Xu; D J Wood; M H Zheng
Journal:  Am J Pathol       Date:  2000-03       Impact factor: 4.307

4.  Deletion of aspartate 182 in OPG causes juvenile Paget's disease by impairing both protein secretion and binding to RANKL.

Authors:  Catherine Middleton-Hardie; Qing Zhu; Harry Cundy; Jian-Ming Lin; Karen Callon; Pak Cheung Tong; Jiake Xu; Andrew Grey; Jill Cornish; Dorit Naot
Journal:  J Bone Miner Res       Date:  2005-11-14       Impact factor: 6.741

5.  A TNF receptor loop peptide mimic blocks RANK ligand-induced signaling, bone resorption, and bone loss.

Authors:  Kazuhiro Aoki; Hiroaki Saito; Cecile Itzstein; Masaji Ishiguro; Tatsuya Shibata; Roland Blanque; Anower Hussain Mian; Mariko Takahashi; Yoshifumi Suzuki; Masako Yoshimatsu; Akira Yamaguchi; Pierre Deprez; Patrick Mollat; Ramachandran Murali; Keiichi Ohya; William C Horne; Roland Baron
Journal:  J Clin Invest       Date:  2006-05-04       Impact factor: 14.808

6.  Amyloid beta-peptide stimulates nitric oxide production in astrocytes through an NFkappaB-dependent mechanism.

Authors:  K T Akama; C Albanese; R G Pestell; L J Van Eldik
Journal:  Proc Natl Acad Sci U S A       Date:  1998-05-12       Impact factor: 11.205

7.  Regulation of cancer cell migration and bone metastasis by RANKL.

Authors:  D Holstead Jones; Tomoki Nakashima; Otto H Sanchez; Ivona Kozieradzki; Svetlana V Komarova; Ildiko Sarosi; Sean Morony; Evelyn Rubin; Renu Sarao; Carlo V Hojilla; Vukoslav Komnenovic; Young-Yun Kong; Martin Schreiber; S Jeffrey Dixon; Stephen M Sims; Rama Khokha; Teiji Wada; Josef M Penninger
Journal:  Nature       Date:  2006-03-30       Impact factor: 49.962

Review 8.  Bone resorption by osteoclasts.

Authors:  S L Teitelbaum
Journal:  Science       Date:  2000-09-01       Impact factor: 47.728

9.  A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function.

Authors:  D M Anderson; E Maraskovsky; W L Billingsley; W C Dougall; M E Tometsko; E R Roux; M C Teepe; R F DuBose; D Cosman; L Galibert
Journal:  Nature       Date:  1997-11-13       Impact factor: 49.962

10.  The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts.

Authors:  T L Burgess; Y Qian; S Kaufman; B D Ring; G Van; C Capparelli; M Kelley; H Hsu; W J Boyle; C R Dunstan; S Hu; D L Lacey
Journal:  J Cell Biol       Date:  1999-05-03       Impact factor: 10.539

View more
  6 in total

1.  A Novel Therapeutic Peptide as a Partial Agonist of RANKL in Ischemic Stroke.

Authors:  Hitomi Kurinami; Munehisa Shimamura; Hironori Nakagami; Hideo Shimizu; Hiroshi Koriyama; Tomohiro Kawano; Kouji Wakayama; Hideki Mochizuki; Hiromi Rakugi; Ryuichi Morishita
Journal:  Sci Rep       Date:  2016-11-29       Impact factor: 4.379

2.  Cytoskeleton-centric protein transportation by exosomes transforms tumor-favorable macrophages.

Authors:  Zhipeng Chen; Lijuan Yang; Yizhi Cui; Yanlong Zhou; Xingfeng Yin; Jiahui Guo; Gong Zhang; Tong Wang; Qing-Yu He
Journal:  Oncotarget       Date:  2016-10-11

3.  Therapeutic Effects of Systemic Administration of the Novel RANKL-Modified Peptide, MHP1, for Ischemic Stroke in Mice.

Authors:  Munehisa Shimamura; Hironori Nakagami; Hideo Shimizu; Kouji Wakayama; Tomohiro Kawano; Yuka Ikeda; Hiroki Hayashi; Shota Yoshida; Hideki Mochizuki; Ryuichi Morishita
Journal:  Biomed Res Int       Date:  2018-07-30       Impact factor: 3.411

4.  A novel modified RANKL variant can prevent osteoporosis by acting as a vaccine and an inhibitor.

Authors:  Young Jong Ko; Hong Moon Sohn; Yuria Jang; Mineon Park; Bora Kim; Beomchang Kim; Jae-Il Park; Hoon Hyun; Byeongseok Jeong; Chansik Hong; Wonbong Lim
Journal:  Clin Transl Med       Date:  2021-03

Review 5.  Receptor Specificity Engineering of TNF Superfamily Ligands.

Authors:  Fengzhi Suo; Xinyu Zhou; Rita Setroikromo; Wim J Quax
Journal:  Pharmaceutics       Date:  2022-01-13       Impact factor: 6.321

Review 6.  Identification of novel mutation in RANKL by whole-exome sequencing in a Thai family with osteopetrosis; a case report and review of RANKL osteopetrosis.

Authors:  Pongtawat Lertwilaiwittaya; Bhoom Suktitipat; Phongphak Khongthon; Warut Pongsapich; Chanin Limwongse; Manop Pithukpakorn
Journal:  Mol Genet Genomic Med       Date:  2021-05-30       Impact factor: 2.183

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.